OTTAWA--Drug regulation in Canada is carried out in a very secretive manner because of the cozy relationship between the brand-name pharmaceutical industry and the Therapeutic Products Directorate (TPD), the arm of Health Canada in charge of testing and approving new drugs.
This is the central finding of a new CCPA study by Dr. Joel Lexchin, Associate Professor in the School of Health...
Over the last 30 years, the CCPA has provided alternative research and analysis that have been indispensable in exposing the corporate agenda. I don’t know what I’d have done without them.